Brest

• Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting
  2024-515787-31-00 5 2025-07-18 Patient with early triple-negative breast cancer (TNBC) achieving path
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting
  2024-516418-39-00 5 2025-07-09 Multiple Myeloma
• An Open-Label, Phase 2 Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with … Recruiting
  2024-519964-42-00 4 2025-07-02 Thrombocythaemia
• Evaluating ivonescimab as a potential treatment for pleural mesothelioma patients whose cancer has returned after previous immunotherapy and … Recruiting
  2024-519052-82-00 4 2025-06-30 pleural mesothelioma
• A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren’s diseas … Recruiting
  2024-514596-18-00 9 2025-06-20 Difficult to treat rheumatoid arthritis
• Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf … Recruiting
  2024-519991-18-00 6 2025-06-16 Rheumatoid Arthritis
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona … Recruiting
  2024-517457-27-00 5 2025-06-04 Chronic Obstructive Pulmonary Disease (COPD)
• Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting
  2023-506935-14-01 5 2025-06-01 Ischemic stroke
• Dose Range Finding Study to Access Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium-to-High Dose Inhaled Cort … Recruiting
  2024-519116-14-00 4 2025-05-27 Asthma
• ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca … Recruiting
  2023-504511-32-00 5 2025-05-24 Any patients ≥18 years old, eligible for transfemoral TAVI with covera
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2024-517513-32-00 5 2025-05-16 Sjögren’s Syndrome
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Randomized clinical trial to compare oral isotretinoin to standard of care in moderate acne skin of color patients Recruiting
  2023-507519-36-00 5 2025-04-29 Acne
• Best hypnotic drug choice for rapid sequence induction in the operating room: a 3-arm randomized trial open-labelled with blinded evaluation … Recruiting
  2024-517582-16-00 5 2025-04-14 rapid sequence induction in the operating room
• ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2024-512043-22-00 4 2025-04-11 Metastatic prostate cancer
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting
  2024-512729-10-00 4 2025-03-27 Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
• 68Gallium-FAPI PET/CT imaging in Chronic inflammatory and fibrotic diseases (PARADISE study) Recruiting
  2023-508190-84-01 4 2025-03-13 Inflammatory disorders
• First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran … Recruiting
  2023-503326-39-00 5 2025-03-06 Synchronous oligometastatic non-small cell lung cancer (NSCLC)
• Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastat … Recruiting
  2023-507873-16-00 11 2025-03-04 1st line treatment for unresectable metastatic colorectal cancer
• A study to learn more about how well treatment with sevabertinib (BAY2927088) tablets works and how safe it is in participants who have a so … Recruiting
  2024-517419-62-00 4 2025-02-28 HER2 mutation

Showing 169–192 of 490 trials